Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2

被引:81
作者
Ward, Richard A. [1 ]
Coldough, Nicola [1 ]
Challinor, Mairi [1 ]
Debreczeni, Judit E. [1 ]
Eckersley, Kay [1 ]
Fairley, Gary [1 ]
Feron, Lyman [1 ]
Flemington, Vildd [1 ]
Graham, Mark A. [1 ]
Greenwood, Ryan [1 ]
Hoperoft, Philip [1 ]
Howard, Tina D. [1 ]
James, Michael [1 ]
Jones, Clifford D. [1 ]
Jones, Christopher R. [1 ]
Renshaw, Jonathan [1 ]
Roberts, Karen [1 ]
Snow, Lindsay [1 ]
Tonge, Michael [1 ]
Yeung, Kay [1 ]
机构
[1] AstraZeneca, Oncol & Discovery Sci iMeds, Macclesfield SK10 4TG, Cheshire, England
关键词
ACQUIRED-RESISTANCE; MEK INHIBITION; DISCOVERY; KINASE; BRAF; MUTATIONS; MELANOMA; MECHANISM; AFFINITY; RECEPTOR;
D O I
10.1021/acs.jmedchem.5b00466
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The RAS/RAF/MEK/ERK signaling pathway has been targeted with a number of small molecule inhibitors in oncology clinical development across multiple disease indications. Importantly, cell lines with acquired resistance to B-RAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition by small molecule inhibitors. There are a number of selective, noncovalent ERK1/2 inhibitors reported along with the promiscuous hypothemycin (and related analogues) that act via a covalent mechanism of action. This article reports the identification of multiple series of highly selective covalent ERK1/2 inhibitors informed by structure-based drug design (SBDD). As a starting point for these covalent inhibitors, reported ERK1/2 inhibitors and a chemical series identified via high-throughput screening were exploited. These approaches resulted in the identification of selective covalent tool compounds for potential in vitro and in vivo studies to assess the risks and or benefits of targeting this pathway through such a mechanism of action.
引用
收藏
页码:4790 / 4801
页数:12
相关论文
共 33 条
[1]  
[Anonymous], 2000, Eurofins (Millipore), Patent No. [WO 2007070398, 2007070398]
[2]   Flipped out: Structure-guided design of selective pyrazolylpyrrole ERK inhibitors [J].
Aronov, Alex M. ;
Baker, Christopher ;
Bemis, Guy W. ;
Cao, Jingrong ;
Chen, Guanjing ;
Ford, Pamella J. ;
Germann, Ursula A. ;
Green, Jeremy ;
Hale, Michael R. ;
Jacobs, Marc ;
Janetka, James W. ;
Maltais, Francois ;
Martinez-Botella, Gabriel ;
Namchuk, Mark N. ;
Straub, Judy ;
Tang, Qing ;
Xie, Xiaoling .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (06) :1280-1287
[3]   Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control [J].
Aronov, Alex M. ;
Tang, Qing ;
Martinez-Botella, Gabriel ;
Bemis, Guy W. ;
Cao, Jingrong ;
Chen, Guanjing ;
Ewing, Nigel P. ;
Ford, Pamella J. ;
Germann, Ursula A. ;
Green, Jeremy ;
Hale, Michael R. ;
Jacobs, Marc ;
Janetka, James W. ;
Maltais, Francois ;
Markland, William ;
Namchuk, Mark N. ;
Nanthakumar, Suganthini ;
Poondru, Srinivasu ;
Straub, Judy ;
ter Haar, Ernst ;
Xie, Xiaoling .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (20) :6362-6368
[4]  
Barlaam B. C., 2009, Patent, Patent No. [WO 2009153589, 2012036997, WO 2012036997]
[5]  
Barlaam B.C., 2009, Patent, Patent No. [WO 2009153589, 2009153589, WO2009/153589]
[6]   Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2 [J].
Blake, James F. ;
Gaudino, John J. ;
De Meese, Jason ;
Mohr, Peter ;
Chicarelli, Mark ;
Tian, Hongqi ;
Garrey, Rustam ;
Thomas, Allen ;
Siedem, Christopher S. ;
Welch, Michael B. ;
Kolakowski, Gabrielle ;
Kaus, Robert ;
Burkard, Michael ;
Martinson, Matthew ;
Chen, Huifen ;
Dean, Brian ;
Dudley, Danette A. ;
Gould, Stephen E. ;
Pacheco, Patricia ;
Shahidi-Latham, Sheerin ;
Wang, Weiru ;
West, Kristina ;
Yin, Jianping ;
Moffat, John ;
Schwarz, Jacob B. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (12) :2635-2639
[7]   Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase [J].
Deng, Yongqi ;
Shipps, Gerald W., Jr. ;
Cooper, Alan ;
English, Jessie M. ;
Annis, D. Allen ;
Carr, Donna ;
Nan, Yang ;
Wang, Tong ;
Zhu, Hugh Y. ;
Chuang, Cheng-Chi ;
Dayananth, Priya ;
Hruza, Alan W. ;
Xiao, Li ;
Jin, Weihong ;
Kirschmeier, Paul ;
Windsor, William T. ;
Samatar, Ahmed A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (21) :8817-8826
[8]   MAP kinase signalling pathways in cancer [J].
Dhillon, A. S. ;
Hagan, S. ;
Rath, O. ;
Kolch, W. .
ONCOGENE, 2007, 26 (22) :3279-3290
[9]   MEK1 mutations confer resistance to MEK and B-RAF inhibition [J].
Emery, Caroline M. ;
Vijayendran, Krishna G. ;
Zipser, Marie C. ;
Sawyer, Allison M. ;
Niu, Lili ;
Kim, Jessica J. ;
Hatton, Charles ;
Chopra, Rajiv ;
Oberholzer, Patrick A. ;
Karpova, Maria B. ;
MacConaill, Laura E. ;
Zhang, Jianming ;
Gray, Nathanael S. ;
Sellers, William R. ;
Dummer, Reinhard ;
Garraway, Levi A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (48) :20411-20416
[10]   Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor [J].
Finlay, M. Raymond V. ;
Anderton, Mark ;
Ashton, Susan ;
Ballard, Peter ;
Bethel, Paul A. ;
Box, Matthew R. ;
Bradbury, Robert H. ;
Brown, Simon J. ;
Butterworth, Sam ;
Campbell, Andrew ;
Chorley, Christopher ;
Colclough, Nicola ;
Cross, Darren A. E. ;
Currie, Gordon S. ;
Grist, Matthew ;
Hassall, Lorraine ;
Hill, George B. ;
James, Daniel ;
James, Michael ;
Kemmitt, Paul ;
Klinowska, Teresa ;
Lamont, Gillian ;
Lamont, Scott G. ;
Martin, Nathaniel ;
McFarland, Heather L. ;
Mellor, Martine J. ;
Orme, Jonathon P. ;
Perkins, David ;
Perkins, Paula ;
Richmond, Graham ;
Smith, Peter ;
Ward, Richard A. ;
Waring, Michael J. ;
Whittaker, David ;
Wells, Stuart ;
Wrigley, Gail L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) :8249-8267